Application for Admission

RNS Number : 5378G

Advanced Medical Solutions Grp PLC

06 November 2018

 

6 November 2018

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Application for Admission

Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that an application has been made to the London Stock Exchange for the admission of a total of 10,176,713 ordinary shares of 5 pence each (the "Ordinary Shares") to trading on AIM.

Further to the announcement on 31 August 2018 and following a full reconciliation of shares previously allotted, all of the Ordinary Shares to which this application relates have been previously issued and allotted under various employee share schemes. As a result, following the admission of these Ordinary Shares, there will be no change to the Group's current issued share capital, which consists of 213,454,651 Ordinary Shares with voting rights.

It is expected that admission will become effective for the Ordinary Shares on 12 November 2018.

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: [phone]
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer
Consilium Strategic Communications	Tel: [phone]
Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser	[e-mail]
Investec Bank PLC (NOMAD & Broker)	Tel: [phone]
Daniel Adams / Patrick Robb / Gary Clarence

About Advanced Medical Solutions Group plc - see www.admedsol.com 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 600 employees.  For more information, please see www.admedsol.com.

 

END

 

 

ALSBLBDBIDGBGIL